[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353642-105":59,"doc-detail-353642-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","harnessing-nanomedicine-to-target-nf-b-signalling-in-cancer-at-the-intersection-of-inflammatory-signalling-metabolic-reprogramming-and-therapeutic-innovation","Harnessing nanomedicine to target NF-κB signalling in cancer - at the intersection of inflammatory signalling, metabolic reprogramming, and therapeutic innovation","","The NF-κB signalling pathway coordinates inflammation, tumour progression, immune modulation, and metabolic reprogramming within the tumour microenvironment. Persistent NF-κB activation is linked to proliferation, therapy resistance, and poor outcomes, while conventional inhibitors suffer from systemic toxicity, limited bioavailability, and insufficient tumour specificity. Nanomedicine enables tumour-targeted delivery of NF-κB modulators, using small molecules, RNA interference, and gene-editing. Reviewed advances in liposomes, polymeric nanoparticles, exosomes, and dendrimers improve therapeutic indices, stability, and reduce off-target effects. Preclinical and translational challenges, plus future AI- and theranostic-guided strategies, are discussed to support clinical adoption.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/harnessing-nanomedicine-to-target-nf-b-signalling-in-cancer-at-the-intersection-of-inflammatory-signalling-metabolic-reprogramming-and-therapeutic-innovation/353642/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/harnessing-nanomedicine-to-target-nf-b-signalling-in-cancer-at-the-intersection-of-inflammatory-signalling-metabolic-reprogramming-and-therapeutic-innovation/353642.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is NF-κB signalling important in cancer and the tumour microenvironment?","Question",{"text":113,"@type":114},"NF-κB signalling orchestrates inflammation, tumour progression, immune modulation, and metabolic reprogramming in the tumour microenvironment, supporting key cancer hallmarks.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What limitations affect conventional NF-κB inhibitors?",{"text":118,"@type":114},"Conventional inhibitors are constrained by systemic toxicity, poor bioavailability, and lack of tumour specificity, which can limit clinical benefit.",{"name":120,"@type":111,"acceptedAnswer":121},"How does nanomedicine address the challenges of targeting NF-κB in cancer?",{"text":122,"@type":114},"Nanomedicine improves specificity and safety by delivering NF-κB modulators directly to tumour sites using nanocarriers such as liposomes, polymeric nanoparticles, exosomes, and dendrimers.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353642,1790145858,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":36,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","BharathwajChetty et al. Cell Communication and Signaling (2026) 24:84  \n[https://doi.org/10.1186/s12964-025-02554-9](https://doi.org/10.1186/s12964-025-02554-9)  \nCell Communication and Signaling  \nREVIEW Open Access  \nHarnessing nanomedicine to target NF- κB signalling in cancer: at the intersection of inflammatory signalling, metabolic reprogramming, and therapeutic innovation  \nBandari BharathwajChetty1, Babu Santha Aswani1, Shweta S. Shinde 1, Mohammed S. Alqahtani2,3, Mohamed Abbas4, Gautam Sethi5,6, Zhaowu Ma7* and Ajaikumar B. Kunnumakkara 1*  \nAbstract  \nThe nuclear factor kappa B (NF-κB) signalling pathway is a pivotal orchestrator of inflammation, tumour progression, immune modulation, and metabolic reprogramming within the dynamic landscape of the tumour microenvironment (TME) . Aberrant and sustained activation of NF-κB is frequently associated with tumour proliferation, resistance to therapy, and poor clinical outcomes. However, conventional NF-κB inhibitors face significant limitations, including systemic toxicity, poor bioavailability, and lack of tumour specificity. Nanomedicine offers a transformative approach to overcome these barriers by enabling the targeted delivery of NF-κB modulators, such as small molecules, RNA interference agents, and gene-editing systems, directly to tumour sites. Recent advances in nanocarriers, including liposomes, polymeric nanoparticles, exosomes, and dendrimers, have demonstrated improved therapeutic indices, enhanced stability, and reduced off-target effects. This review highlights the convergence of nanotechnology, inflammatory signalling, and cancer metabolism, with a focus on how nanomedicine can precisely modulate NF-κB signalling to reprogramme tumour-associated macrophages and remodel the TME. It also discusses preclinical evidence supporting NF-κB-targeted nanomedicine, innovative delivery strategies, and the translational challenges that impede clinical adoption. Collectively, these insights highlight the potential of nanomedicine in advancing NF-κB-targeted cancer therapy by enhancing drug specificity, safety, and therapeutic responsiveness. Future developments integrating artificial intelligence, theranostic design, and personalised nanomedicine are expected to accelerate clinical translation and establish NF-κB-targeted nanotherapeutics as a cornerstone of next-generation precision oncology.  \n*Correspondence:  \nZhaowu Ma[mazw@yangtzeu.edu.cn](mazw@yangtzeu.edu.cn)[ ](mazw@yangtzeu.edu.cn)Ajaikumar B. Kunnumakkara[kunnumakkara@iitg.ac.in](kunnumakkara@iitg.ac.in)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nBharathwajChetty et al. Cell Communication and Signaling (2026) 24:84 Page 2 of 40  \nGraphical Abstract  \nKeywords NF-κB pathway, Nanomedicine, Tumour microenvironment, Immune reprogramming, Therapeutic resista","cbCaivTWuHOiXs3L","https://ap.wps.com/l/cbCaivTWuHOiXs3L","pdf",8326614,"English","# Abstract\n# Keywords\n# Background\n## Cancer burden and prognosis\n## Drivers of cancer progression and metabolism\n## Tumour microenvironment as a therapeutic target","[{\"question\":\"Why is NF-κB signalling important in cancer and the tumour microenvironment?\",\"answer\":\"NF-κB signalling orchestrates inflammation, tumour progression, immune modulation, and metabolic reprogramming in the tumour microenvironment, supporting key cancer hallmarks.\"},{\"question\":\"What limitations affect conventional NF-κB inhibitors?\",\"answer\":\"Conventional inhibitors are constrained by systemic toxicity, poor bioavailability, and lack of tumour specificity, which can limit clinical benefit.\"},{\"question\":\"How does nanomedicine address the challenges of targeting NF-κB in cancer?\",\"answer\":\"Nanomedicine improves specificity and safety by delivering NF-κB modulators directly to tumour sites using nanocarriers such as liposomes, polymeric nanoparticles, exosomes, and dendrimers.\"}]","Harnessing nanomedicine to target NF-κB signalling in cancer - at the intersection of inflammatory signalling, metabolic reprogramming, and therapeutic innovation | PDF",1790106513,101,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bc00199dac2a5a9a2de99006480543d.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f8640668fd1e0bca5d529ce6cdbec8c.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/734196be7b3ec15fa75f88cac779042c.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f753cfd708932fd50eb01146bda8c71d.webp",980,1306]